T-Therapeutics, a biotechnology company based in Cambridge, UK, has raised $133 million in an oversubscribed Series B financing round to advance its experimental treatments for cancer and autoimmune diseases towards clinical trials.
Announced on November 5, 2026, the funding round was co-led by Advent Life Sciences and British Business Bank. New investors also include Johnson & Johnson Innovation, Samsara BioCapital, M-Ventures and Eli Lilly. Existing investors, including Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent and BGF, also participated.
The company plans to use the funding to advance two lead drug development programmes based on its T-cell receptor (TCR) technology. The programmes focus on cancer, particularly solid tumours, and autoimmune diseases, with the goal of generating early clinical proof-of-concept data.
T-Therapeutics is developing a new type of treatment called TCR-CD3 bispecific therapy. These therapies are designed to help the body’s immune system identify and attack specific disease-causing cells.
Unlike many existing antibody-based treatments that mainly target proteins found on the surface of cells, TCR-based therapies can recognise protein fragments that come from inside cells. This could allow researchers to target disease-related proteins that have been difficult to reach with conventional medicines.
The company’s proprietary OpTiMus platform plays a central role in this approach. It provides a supply of fully human T-cell receptors that can recognise these targets. The receptors are then developed into bispecific medicines designed to connect disease-associated targets with CD3, a protein found on T cells, helping direct the immune system towards the targeted cells.
In cancer, T-Therapeutics is developing a programme aimed at solid tumours. The company believes this approach could open new treatment opportunities across several cancer types, particularly where existing T-cell engager therapies have faced challenges.
Its second programme focuses on autoimmune diseases and chronic tissue inflammation. The goal is to selectively remove harmful immune cells responsible for driving inflammation while avoiding broad suppression of the immune system.
Alongside the funding announcement, T-Therapeutics has appointed Dr. Kirsty Crame as its Chief Development Officer. She will oversee the development of the company’s drug candidates, including their preparation for clinical testing.
Dr. Crame brings more than 15 years of experience in drug development. She previously served as Chief Medical Officer at Curatis AG and held roles at Medigene AG and Gadeta BV, where she worked on early-stage clinical programmes and TCR-based therapies.
The company’s CEO, Theodora Harold, said the financing marks an important step in its move towards becoming a clinical-stage biotechnology company. She highlighted the potential of its technology to reach disease targets that have remained difficult to address with existing treatments.
Following the investment, representatives from Advent Life Sciences, British Business Bank, Johnson & Johnson Innovation and Samsara BioCapital will also join the company’s board as non-executive directors.
The $133 million financing gives T-Therapeutics additional resources to move its two lead programmes into clinical development. The next important milestone will be demonstrating whether its TCR bispecific approach can deliver meaningful results in patients with cancer and autoimmune diseases.
If successful, the technology could expand the range of targets available for T-cell-based treatments and create new options for patients who have limited treatment choices.